Jane Owens, D.V.M., Ph.D., JGO Consulting
Dr. Jane Owens received a B.S. in Animal Science from the University of Kentucky and her D.V.M. from Tuskegee University, School of Veterinary Medicine. She completed her doctoral training in equine pharmacology at the department of veterinary physiology, pharmacology and toxicology at Louisiana State University and her doctoral fellowship at the Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina.
Dr. Owens has worked in the animal health pharmaceutical industry for 26 years to discover, develop and register new drugs for all veterinary species including dogs, cats, horses and food animals. She started her career in industry at Pfizer Animal Health in Connecticut before moving to Indiana to join Elanco Animal Health.
Dr. Owens is board certified by the American College of Veterinary Clinical Pharmacology and is the past president of the American Academy of Veterinary Pharmacology and Therapeutics. She also serves as president and founding member of the Veterinary Pharmacology Research Foundation. Dr. Owens has participated in several American Veterinary Medical Association committees and is the past chair of the Council on Biologic and Therapeutic Agents. She also serves on the Scientific Review Committee of the American Kennel Club's Canine Health Foundation and the Veterinary Pharmacology Research Foundation. Her interests include breeding horses and keeping up with her Irish terrier, Darcy.
Kara Raetzel, D.V.M., Elanco Animal Health
Dr. Kara Raetzel is currently a senior technical consultant at Elanco Animal Health, where she provides technical support to both veterinarians and pet owners as well as the reporting and investigation of potential product related adverse events. Prior to working at Elanco, she held a similar position at Bayer Animal Health, where she also provided technical and medical review of marketing pieces. She entered industrial veterinary medicine following 15 years of companion animal practice after obtaining a veterinary degree at Kansas State University.
Dr. Raetzel's professional interests include companion animal medicine, client education, infectious disease, vector borne diseases, pharmacovigilance and vaccines.
"Pharmacovigilance objectively provides information about the ongoing safety and efficacy of our products as they reach a larger population, putting product risk of usage into perspective within the pharmaceutical industry," she says.
John Schiltz, D.V.M., USDA
Dr. John Schiltz received his D.V.M. degree from Iowa State University. Work experience includes private practice, State Veterinarian for Iowa, Diagnostic Virology Lab, Swine Program staff and currently with the Center for Veterinary Biologics. Dr. Schiltz will discuss the requirements and implications of the new mandatory adverse event reporting regulation.
Martin Tiemann, D.V.M., Boehringer-Ingelheim
With a veterinary degree from the University of Montreal, Dr. Martin Tiemann spent 20 years in mixed animal practice between Montreal and Ottawa in Canada. He joined Industry with Merial Canada as the manager of RA, QA and Technical Services. Martin came to the U.S. to take a director of pharmacovigilance and product stewardship with Intervet in Delaware. Following a series of acquisitions by Schering Plough and then Merck, Martin chose to move to the Midwest in 2009 to work for Boehringer Ingelheim, he has had several roles in RA and PV, including serving as the head of global pharmacovigilance from 2018 to 2020. Since November 2020, Martin is the head of Pharmacovigilance and Veterinary Technical Services NA at Boehringer Ingelheim Animal Health U.S.